1. Compound Overview

Tirzepatide is a synthetic 39-amino-acid peptide incorporating structural modifications that extend its biological duration. It was developed as a single molecular entity capable of activating both GIP and GLP-1 receptors.

GIP and GLP-1 are endogenous incretin hormones released in response to nutrient ingestion. Both participate in glucose-dependent endocrine signaling, although their physiological roles and receptor distributions are not identical.

The development of tirzepatide was based on the hypothesis that coordinated activation of the two incretin systems could produce a distinct pharmacological profile compared with selective GLP-1 receptor activation.

2. Incretin Biology

The incretin effect describes the greater insulin response observed when glucose is delivered orally compared with an equivalent intravenous glucose exposure. This phenomenon reflects the contribution of gastrointestinal hormones to glucose-dependent pancreatic signaling.

GIP and GLP-1 are the principal incretin hormones involved in this physiology. GIP is secreted predominantly by K cells in the proximal small intestine, while GLP-1 is produced primarily by intestinal L cells.

Following nutrient exposure, these hormones interact with receptors expressed on pancreatic and other target cells. Their signaling can influence insulin secretion and other aspects of metabolic regulation.

GIP

Glucose-dependent insulinotropic polypeptide, historically known as gastric inhibitory polypeptide, is an incretin hormone that contributes to nutrient-dependent insulin secretion.

GIP receptor activation can stimulate intracellular cyclic AMP signaling and influence pancreatic beta-cell function. Research has also investigated GIP signaling in adipose tissue and the central nervous system.

GLP-1

GLP-1 contributes to glucose-dependent insulin secretion and participates in regulation of glucagon, gastrointestinal function, and food intake.

Selective GLP-1 receptor agonists have therefore become an important pharmacological class for metabolic research. Tirzepatide extends this approach by activating both GLP-1R and GIPR.

3. Dual GIP and GLP-1 Receptor Activity

The defining feature of tirzepatide is its ability to engage two incretin receptors with a single molecular structure.

Coskun and colleagues described tirzepatide as a dual GIP and GLP-1 receptor agonist and characterized its activity in cellular and animal models during the original preclinical development program.

The resulting pharmacological model differs from simply combining two unrelated drugs. Tirzepatide is one peptide with receptor activity at both GIPR and GLP-1R, allowing the two signaling systems to be activated within the same pharmacological exposure.

4. GIP Receptor Signaling

The GIP receptor is a class B G-protein-coupled receptor expressed in pancreatic beta cells and other tissues involved in metabolic physiology.

Activation of GIPR can stimulate adenylyl cyclase and increase intracellular cyclic AMP. Downstream signaling contributes to glucose-dependent insulin secretion and other cellular responses.

GIP biology is particularly relevant to understanding tirzepatide because GIPR activity is one of the features that distinguishes the compound from selective GLP-1 receptor agonists.

GIP signaling beyond the pancreas

GIP receptors have also been investigated in adipose tissue and neural systems. Experimental research has explored the hormone's influence on lipid metabolism, adipocyte biology, and central regulation of energy balance.

However, evidence for the contribution of these pathways to specific human outcomes remains more complex than the established role of incretin signaling in glucose-dependent insulin secretion.

5. GLP-1 Receptor Signaling

GLP-1 receptor activation forms the second major component of tirzepatide pharmacology.

The GLP-1 receptor is a class B G-protein-coupled receptor. Its activation can stimulate intracellular cyclic AMP signaling and downstream pathways associated with glucose-dependent insulin secretion.

GLP-1 receptor signaling is also involved in gastrointestinal and neural pathways relevant to food intake and appetite regulation.

Because tirzepatide activates GLP-1R as well as GIPR, some of the compound's observed effects overlap with findings previously documented for GLP-1 receptor agonists.

Nevertheless, the presence of GLP-1 receptor activity should not be interpreted as evidence that all tirzepatide responses are mediated exclusively through GLP-1R.

6. Intracellular Signaling

Both GIPR and GLP-1R belong to the class B family of G-protein-coupled receptors and can activate intracellular second-messenger systems involving cyclic AMP.

Following receptor activation, increases in cyclic AMP can influence downstream effectors including protein kinase A and exchange proteins directly activated by cAMP.

In pancreatic beta cells, these signaling events interact with glucose-sensitive pathways to amplify insulin secretion.

Receptor signaling is context-dependent

Receptor activation does not produce an identical response in every cell. The magnitude and biological consequences of signaling depend on receptor expression, intracellular signaling machinery, glucose concentrations, cellular state, and tissue context.

This is important when interpreting mechanistic studies because cellular and animal findings can demonstrate biological plausibility without establishing the magnitude or relevance of the same pathway in humans.

7. Glucose and Metabolic Regulation

The most established physiological framework for tirzepatide involves incretin-mediated regulation of glucose metabolism.

Both GIP and GLP-1 receptor pathways can enhance glucose-dependent insulin secretion. GLP-1 receptor signaling additionally influences glucagon secretion and gastrointestinal physiology.

Tirzepatide has therefore been evaluated extensively in people with type 2 diabetes, with randomized trials examining glycated hemoglobin, fasting glucose, body weight, and other metabolic endpoints.

Glucose-dependent insulin signaling

Incretin receptor signaling is strongly influenced by ambient glucose. This glucose dependence is a central feature of GIP and GLP-1 physiology.

Tirzepatide's ability to activate both receptor pathways provides a pharmacological mechanism for enhancing incretin-mediated insulin responses while engaging additional metabolic signaling.

8. Appetite and Energy-Intake Research

Appetite regulation is another major area of tirzepatide research. Food intake is controlled by interactions among gastrointestinal signals, circulating metabolic factors, endocrine hormones, and neural pathways.

GLP-1 signaling is already known to participate in appetite-related physiology. GIP signaling has also been investigated in relation to energy balance and neural regulation.

Tirzepatide provides an experimental model for examining what happens when both incretin systems are engaged simultaneously.

Energy intake

Clinical research has measured food intake and appetite-related variables in people receiving tirzepatide. These studies have investigated whether observed changes in body weight are accompanied by measurable alterations in energy intake and eating behavior.

In the SURMOUNT-1 trial, for example, tirzepatide was studied in adults with overweight or obesity without diabetes, with body weight and cardiometabolic endpoints serving as major clinical outcomes.

These observations should be interpreted as population-level findings from controlled research rather than predictions of an identical outcome in every individual.

9. Gastrointestinal Signaling

GLP-1 receptor activation can influence gastrointestinal motor function, including gastric emptying. GIP and GLP-1 also participate in broader communication between the gastrointestinal tract and endocrine system.

Gastrointestinal effects are relevant to appetite because nutrient delivery and intestinal signaling contribute to post-meal satiety responses.

However, the relationship between gastric emptying and the broader clinical effects of tirzepatide is complex. Gastrointestinal physiology represents one component of a larger network rather than a complete explanation of all observed outcomes.

10. Clinical Research

Tirzepatide has been investigated through a large clinical development program. The SURPASS trials evaluated its effects in people with type 2 diabetes, while the SURMOUNT program examined tirzepatide in populations with overweight or obesity.

These programs provide compound-specific human evidence and are particularly important when distinguishing tirzepatide findings from general GLP-1 or GIP biology.

SURPASS Program

The SURPASS clinical program evaluated tirzepatide across multiple populations and comparator conditions in type 2 diabetes.

Frias and colleagues reported results from a phase 2 study comparing tirzepatide with dulaglutide, providing early clinical evidence of its glucose-lowering and body-weight-related effects.

Later SURPASS trials compared tirzepatide with established therapies including insulin and other GLP-1 receptor agonists.

SURPASS-2

In SURPASS-2, Frías and colleagues compared once-weekly tirzepatide with semaglutide in people with type 2 diabetes receiving metformin. The study provided direct clinical evidence comparing dual incretin receptor activation with selective GLP-1 receptor agonism.

SURMOUNT-1

Jastreboff and colleagues evaluated tirzepatide in adults with overweight or obesity without diabetes in the SURMOUNT-1 randomized clinical trial.

The trial examined changes in body weight and multiple cardiometabolic variables over the study period.

While these findings provide substantial human evidence concerning clinical outcomes, they do not independently determine the precise contribution of GIPR versus GLP-1R signaling to every observed endpoint.

11. Why Dual Incretin Agonism Is Scientifically Important

The central scientific question surrounding tirzepatide is not simply whether it activates GIPR and GLP-1R, but how simultaneous activation of the two pathways changes the resulting physiological response.

GIP and GLP-1 share certain signaling characteristics while also exhibiting distinct tissue distributions and physiological roles. Consequently, dual receptor activation provides an opportunity to investigate interactions between two incretin systems.

This distinction is important because clinical superiority in a particular endpoint does not, by itself, prove that a particular receptor pathway is responsible. Mechanistic attribution generally requires receptor-selective experimental studies, pharmacological comparisons, and translational evidence.

12. Receptor Pharmacology and Signaling Bias

Incretin receptor pharmacology is not limited to a simple on-or-off model of receptor activation. GPCRs can engage multiple downstream signaling pathways, and different ligands can produce different signaling profiles.

Experimental work on tirzepatide has therefore examined its pharmacological behavior at GIPR and GLP-1R using cellular systems and receptor-signaling assays.

These studies provide important mechanistic information, but signaling behavior measured in recombinant or isolated cellular systems cannot automatically be translated into the magnitude of physiological effects in humans.

13. What the Published Literature Shows

14. Limitations of the Existing Evidence

15. Research Status

Tirzepatide has progressed from preclinical receptor and metabolic research to extensive randomized clinical investigation. The published evidence clearly establishes its pharmacological activity at both GIPR and GLP-1R.

Human clinical trials provide substantial evidence concerning glycemic and body-weight-related outcomes in defined populations. Mechanistic studies additionally support the biological plausibility of dual incretin signaling as a distinct pharmacological strategy.

Nevertheless, the precise physiological contribution of GIP receptor signaling remains an important scientific question. The fact that tirzepatide activates two receptors does not mean that every observed endpoint can be separated cleanly into a GIP component and a GLP-1 component.

16. Conclusion

Tirzepatide represents a distinct pharmacological approach to incretin signaling because a single peptide activates both the GIP and GLP-1 receptors.

The published literature supports a mechanistic framework in which dual receptor activation engages intracellular signaling pathways involved in glucose-dependent insulin secretion and broader metabolic regulation.

Clinical studies have subsequently investigated tirzepatide across populations with type 2 diabetes and overweight or obesity, while experimental research continues to examine how GIPR and GLP-1R signaling interact.

Appetite, energy intake, gastrointestinal physiology, glucose regulation, and body-weight-related outcomes should therefore be viewed as interconnected but distinct research endpoints rather than consequences of a single molecular mechanism.

The most useful scientific interpretation of tirzepatide is as a long-acting dual incretin receptor agonist whose biological activity emerges from simultaneous engagement of two related but pharmacologically distinct signaling systems.